Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399918 · ClinicalTrials.gov registry record · Phase 2
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT01399918: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01399918 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01399918, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer. In this clinical trial we are now testing these medications in combination. We think that both together might work better that either drug alone. Importantly, both of these drugs together have been tested in patients with a different type of kidney cancer and patients tolerated the combination well.
Interventions
- DRUG everolimus and bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-07 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399918
The ClinicalTrials.gov registry entry for NCT01399918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which everolimus and bevacizumab is the first listed.
NCT01399918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399918 about?
NCT01399918 is a clinical study titled "Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)". The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer. In this clinical trial we are now testing these medications in combination. We think that both together might work better that either drug alon...
What is the current status of trial NCT01399918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2011-07. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT01399918?
The interventions under investigation include: everolimus and bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01399918?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.